- Home
- NIXX vs ALXO Comparison
NIXX vs ALXO Comparison
Compare NIXX & ALXO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NIXX
- ALXO
- Stock Information
- Founded
- NIXX 2010
- ALXO 2015
- Country
- NIXX United States
- ALXO United States
- Employees
- NIXX N/A
- ALXO N/A
- Industry
- NIXX
- ALXO Biotechnology: Pharmaceutical Preparations
- Sector
- NIXX
- ALXO Health Care
- Exchange
- NIXX NYSE
- ALXO Nasdaq
- Market Cap
- NIXX 66.8M
- ALXO 76.5M
- IPO Year
- NIXX N/A
- ALXO 2020
- Fundamental
- Price
- NIXX $4.44
- ALXO $1.74
- Analyst Decision
- NIXX
- ALXO Buy
- Analyst Count
- NIXX 0
- ALXO 6
- Target Price
- NIXX N/A
- ALXO $11.00
- AVG Volume (30 Days)
- NIXX 276.1K
- ALXO 1.1M
- Earning Date
- NIXX 11-14-2024
- ALXO 03-06-2025
- Dividend Yield
- NIXX N/A
- ALXO N/A
- EPS Growth
- NIXX N/A
- ALXO N/A
- EPS
- NIXX N/A
- ALXO N/A
- Revenue
- NIXX $668,693.00
- ALXO N/A
- Revenue This Year
- NIXX $209.13
- ALXO N/A
- Revenue Next Year
- NIXX N/A
- ALXO N/A
- P/E Ratio
- NIXX N/A
- ALXO N/A
- Revenue Growth
- NIXX N/A
- ALXO N/A
- 52 Week Low
- NIXX $1.12
- ALXO $1.19
- 52 Week High
- NIXX $8.50
- ALXO $17.83
- Technical
- Relative Strength Index (RSI)
- NIXX N/A
- ALXO 53.13
- Support Level
- NIXX N/A
- ALXO $1.56
- Resistance Level
- NIXX N/A
- ALXO $1.94
- Average True Range (ATR)
- NIXX 0.00
- ALXO 0.16
- MACD
- NIXX 0.00
- ALXO -0.01
- Stochastic Oscillator
- NIXX 0.00
- ALXO 50.00
About NIXX NIXXY INC
Nixxy Inc formerly Recruiter.Com Group Inc is a hiring platform for the network of recruiters. It empowers businesses to recruit specialized talent faster with virtual teams of recruiters and AI job-matching technology. The Recruiter.com network of over 28,000 small and independent recruiters utilize a web platform, complete with AI-driven job matching, to recruit talent faster. Its Recruiters On Demand provides businesses of all sizes access to virtual recruiters specialized by vertical industries to source, engage, and hire talent on an as-needed basis.
About ALXO ALX Oncology Holdings Inc.
ALX Oncology Holdings Inc is a clinical-stage immuno-oncology company focused on helping patients fight cancer by developing a pipeline of product candidates based on expertise in protein engineering and oncology led by the CD47 blocker, evorpacept, currently in phase 1 and 2 clinical trials. Cancer cells leverage CD47, a cell surface protein, as a don't eat me signal to evade detection by the immune system. The company is developing a next-generation checkpoint inhibitor designed to have a high affinity for CD47 and to avoid the limitations caused by hematologic toxicities inherent in other CD47 blocking approaches.